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Summary
Maintaining homoeostatic host–microbe interactions is vital for host 
immune function. The gut microbiota shapes the host immune system and 
the immune system reciprocally shapes and modifies the gut microbiota. 
However, our understanding of how these microbes are tolerated and how 
individual, or communities of, gut microbes influence host function is lim-
ited. This review will focus on metabolites as key mediators of this complex 
host–microbe relationship. It will look at the central role of epithelial me-
tabolism in shaping the gut microbiota, how microbial metabolites influence 
the epithelium and the mucosal and peripheral immune system, and how 
the immune system shapes microbial composition and metabolism. Finally, 
this review will look at how metabolites are involved in cross-talk between 
different members of the microbiota and their role during infections.
Keywords: autoimmunity, dysbiosis, host-pathogen interactions, infection, 
inflammation, physiological hypoxia
Introduction
The intestinal tract is colonized by a plethora of microbes 
known collectively as the gut microbiota. From ants to 
humans, these gut microbes play important roles in main-
taining host physiology: from nutrient acquisition and 
synthesis, energy homoeostasis, maintenance of coloniza-
tion resistance and immune development and maintenance 
[1,2]. Dysbiosis, meaning a disruption in the normal 
microbiota, is associated with a plethora of immune, 
metabolic and even neurological diseases [3–6]. A com-
mon trait in dysbiosis is a shift from obligate anaerobes 
to facultative anaerobe or aerobic microorganisms [7,8]. 
Causes of dysbiosis include environmental factors such 
as antibiotic use and western-style high-fat diet [3], but 
host genetic factors that regulate gut epithelial function 
and oxygen metabolism, or disease states, may also underlie 
dysbiosis [3,7,8]. As such, it is often uncertain whether 
dysbiosis causes disease or is a result [9]. While the 
understanding of host–microbe interactions has advanced 
enormously over the past 20  years, there is still much 
more yet to be defined. With rapidly advancing multiomics 
technologies we are gaining insight into how metabolism, 
and metabolites, are key to supporting the host– 
microbe relationship.
Colonic epithelial metabolism shapes gut microbial 
composition and vice versa
The intestinal epithelium is at the interface of host and 
microbe interactions. Epithelial integrity is vitally important 
for maintaining host health, as loss of barrier integrity 
can lead to dissemination of intestinal bacteria, disruption 
of nutrient acquisition, water loss and activation of mucosal 
inflammation. Epithelial metabolism has been proposed 
to be central in establishing the hypoxic environment of 
the colon lumen that is critical to maintaining obligate 
anaerobic commensal/mutualistic microbes [7], but the 
main energy source of colonocytes is butyrate, a metabolic 
by-product of the gut microbiota, suggesting that micro-
biota presence is the first most important step for estab-
lishing the host–microbe interface. This cyclical relationship 
between host epithelial metabolism providing a niche for 
gut microbes and gut microbes providing an energy source 
for the epithelium, make it difficult to dissect the under-
pinning mechanisms at the basis of host–microbe 
homoeostasis.
Members of the healthy gut microbiota are important 
for the digestion of complex plant polysaccharides (fibre) 
from the diet by fermentation and as such, germ-free 
mice exhibit an enlarged caecum, due to the build-up of 
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undigested dietary fibre, and defects in energy har-
vest  –  particularly in colonocyte energy homoeostasis 
[10–17]. Fermentation of dietary fibre results in the pro-
duction of short chain fatty acid (SCFA), including acetate 
(C2), propionate (C3) and butyrate (C4). It has long been 
established that colonocytes preferentially utilize butyrate 
as an energy source, and doing so utilizes oxygen, with 
butyrate metabolism accounting for approximately 85% 
of oxygen consumption by colonocytes [17–21]. Germ-free 
mice exhibit decreased epithelial nicotinamide adenine 
dinucleotide hydrogen (NADH)/NAD+  and ATP levels, 
marked by decreased mRNA and protein expression of 
various genes involved in metabolism [17], which high-
lights the importance of the microbiota for epithelial 
metabolism. Host colonization starts from birth (the fetus 
is considered largely sterile) and during the first months 
and years microbes inhabiting the gut undergo successive 
waves of colonization. First, pioneering aerobic or faculta-
tive anaerobes dominate before obligate anaerobes assemble 
and diversity appears [22–24]. Experiments in germ-free 
mice indicate that obligate anaerobes cannot colonize the 
intestine without prior colonization with aerobic or fac-
ultative anaerobes [25], which suggests that these pioneers 
are involved in establishing a relationship with the host.
Several studies have begun to unravel the pathways 
involved in regulating colonic epithelial metabolism and 
the interplay between epithelium and gut microbiota. 
[7,17,21,26–28]. As colonic epithelial cells differentiate they 
acquire expression of peroxisome proliferator-activated 
receptor gamma  (PPARγ) [29], which activates fatty acid 
metabolism enabling mitochondrial β-oxidation and oxi-
dative phosphorylation with butyrate as the fuel source 
[17,27]. This utilizes large amounts of oxygen, causing 
very low levels of oxygen at the mucosal surface (<10 mm/
Hg = <1%) [30–32]. Limited oxygen diffusion from the 
mucosal tissue into the gut lumen makes the hypoxic 
environment suitable for harbouring obligate anaerobic 
microbes [7,27]. Obligate anaerobic microbes then pref-
erentially occupy this niche, preventing growth of faculta-
tive anaerobes [7]. A further layer of complexity is that 
butyrate itself activates PPARγ [33], making a closed 
circuit of mutual benefit, but also making it difficult to 
ascertain where the cycle initially starts (Fig. 1). As 
described above, obligate anaerobes cannot colonize a 
germ-free host without the prior colonization with an 
aerobic organism. This suggests that early microbial signals 
may be required to instigate the transcriptional network 
that activates PPARγ and subsequent high levels of oxygen 
utilization.
Given that enterocytes at the tip of the colonic crypt 
exist in a virtually hypoxic environment, they must need 
to adapt to these conditions to prevent cell death. It has 
been demonstrated that butyrate metabolism and 
subsequent oxygen utilization is sufficient to stabilize 
hypoxia-inducible factor (HIF) in the colonic epithelium 
[21]. HIF stabilization is important for activating a cel-
lular signature of physiological hypoxia, inducing numerous 
targets that are involved in maintaining barrier function 
[34]. For example, HIF binds to intestinal trefoil factor 
(ITF), an important mediator of barrier function [26]. 
Thus, enterocytes are adapted to function and maintain 
barrier integrity within this physiological hypoxic 
environment.
Together, these studies suggest that establishment of 
the transcriptional networks that enable high oxygen 
consumption by colonocytes and ability to function in 
physiological hypoxia is critical to establishing the host–
microbe relationship, and that early pioneering gut 
microbes may be required to initiate such transcriptional 
networks. Perturbations in epithelial metabolism (genetic, 
disease, damage, other) or perturbations in the gut 
microbiota (antibiotics, diet, infection, inflammation, 
other) could disrupt this host–microbe metabolic inter-
dependence. Future studies looking to unravel the com-
plex interplay between host epithelium, microbiota and 
establishment of this physiological hypoxia may need 
to look at the events during early host colonization in 
order to understand more clearly what the first signals 
are that activate this cyclic interaction between host 
and microbe. These pathways are less studied in the 
small intestine, but physiological hypoxia is also appar-
ent in the small intestine [35]. Future studies might 
also look into the effect of fluctuations in blood flow 
and thereby oxygen abundance, which occurs following 
feeding. Just a fraction of mucosal capillaries are used 
under fasting conditions, whereas in the fed state intes-
tinal blood flow can increase up to 200% [35]. An 
interesting question is whether an overfed state, such 
as that which typically occurs in developed countries 
where food is abundant, could lead to increased oxy-
genation of the intestinal villus and lumen leading to 
altered microbiomes overserved in western cultures, 
contributing to dysbiosis and disease development or 
amplification.
Commensal metabolites and their effects on the 
intestinal epithelium
The gut microbiota have enormous effects on the host, 
not only through the presence of microbe-associated 
molecular patterns (MAMPs), but also through metabo-
lites they generate. As discussed above, fermentation of 
dietary fibre results in SCFA production, and butyrate 
is particularly important for intestinal epithelial homoeo-
stasis. Butyrate also has further effects on epithelial cells 
through inhibition of histone deacetylases (HDACs) [36] 
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and butyrate, as well as the other SCFAs, acetate and 
propionate, also have roles in regulating immune func-
tions, which will be discussed later. Aside from SCFA, 
many other metabolites have been found to directly 
influence the intestinal epithelium, which will be discussed 
more here.
Lactic-acid producing bacteria (LAB) are known to 
exert a range of beneficial effects on gut homoeostasis 
and mucosal and systemic immunity [37–40], but the 
mechanisms of action are not well characterized. A 
recent study has shown direct effects of lactate produced 
by LAB on Paneth cells and submucosal stromal cells 
via G-protein coupled receptor 81 (GPR81) [41], a 
lactate-specific receptor [42–44]. Production of Wnt 
ligands by Paneth cells is important for the maintenance 
of stem cells [45]. Intestinal stromal cells and subepi-
thelial mesenchymal cells also express Wnt ligands, and 
have also been shown to support intestinal stem cells 
[46,47]. Lee et al. [41] found that GPR81 is expressed 
on Paneth and submucosal stromal cells, and that 
engagement of lactate induced Wnt ligands resulting 
in differentiation of intestinal stem cells [41]. 
Functionally, lactate provided by LAB, or supplementa-
tion in the drinking water, improved intestinal repair 
following radiation and chemotherapy-induced damage 
when given prophylactically [41]. LAB deficient in lactate 
dehydrogenase, and thereby lactate production, could 
not exert this beneficial effect, and Gpr81–/– mice have 
defective intestinal regeneration due to impaired Wnt3 
activation [41].
Fig. 1. Metabolic interplay between host and gut microbes. Colonic epithelial metabolism of butyrate is central to establishing the host–microbe 
relationship. Butyrate is a by-product of fermentation of dietary and host-derived complex carbohydrates. Certain species of the gut microbiota are 
responsible for short-chain fatty acid (SCFA) production (acetate, propionate and butyrate); these are critical members of the community and 
dysbiosis is often characterized by their loss. Enterocytes at the tip of the villi are main users of butyrate; they express Peroxisome proliferator-
activated receptor gamma (PPARy) (which can be induced by butyrate) which activates β-oxidation and oxidative phosphorylation. High amounts of 
oxygen are consumed in this process, making the top of the intestinal crypts physiologically hypoxic. This ensures limited oxygen diffusion into the 
gut lumen, thereby creating an environment suitable for obligate anaerobes. Hypoxia induces hypoxia-inducible factor (HIF), which activates a 
transcriptional network important for maintaining epithelial integrity. SCFA also have a variety of effects on the mucosal and peripheral immune 
systems, largely acting in a regulatory capacity, limiting inflammatory responses. They also regulate immunoglobulin (Ig)A production via retinoic 
acid production by dendritic cells, which in turn also modulates microbiota composition.
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Amino acid metabolism is regulated by the gut microbiota, 
which affects the amount and type of amino acids available 
to the host [48–50]. Tryptophan is an essential amino acid 
important for the generation of a range of bioactive mol-
ecules, including serotonin and melatonin [51]. The host 
utilizes the majority of diet-derived tryptophan, but the gut 
microbiota also metabolize a portion resulting in indole-
containing molecules [52,53]. Several of these are aryl hydro-
carbon receptor ligands and regulate mucosal immunity, 
which will be discussed in later sections, and is also discussed 
in detail in a review by Roager and Licht [54].
One commensal, Clostridium sporogenes, metabolizes all 
three aromatic amino acids (AAA), including tryptophan. 
Analysis of the metabolic pathway involved revealed that 
there are 12 resulting metabolites, nine of which accu-
mulate in host serum, including indolepropionic acid (IPA) 
[52]. IPA was found to be important for maintaining 
barrier integrity, and lack of IPA and the other AAA 
metabolites increased intestinal permeability [52,55]. IPA 
was shown to bind epithelial pregnane X receptor (PXR), 
inducing down-regulation of tumour necrosis factor 
(TNF)-α and up-regulation of junctional protein-encoding 
mRNAs [55]. Systemic immunity was affected by dimin-
ished IPA production, with increased percentage of neu-
trophils and CD8 T cells and increased anti-C. sporogenes 
immunoglobulin (Ig)A [52]. This work demonstrates that 
active maintenance of the intestinal barrier, as instructed 
by microbial metabolites, is critical for maintaining the 
host tolerance of the gut microbiota.
Tryptamine is a tryptophan-derived monoamine, which 
has structural similarity to 5-hydroxytryptamine (serotonin) 
and is produced by gut microbes. Bhattarai et al. [56] 
observed that microbial-derived tryptamine activates the 
5-HT4 receptor (5-HT4R) on the intestinal epithelium, 
increasing colonic secretion and decreasing the time taken 
for gastric emptying (transit time). Thus, this microbial 
derivative of tryptophan may have important roles in regu-
lating responses to infection which rely on intestinal secre-
tions to flush out the pathogen [56]. Tryptamine, or bacteria 
engineered to produce tryptamine, may also represent a 
novel treatment for diseases distinguished by slow transit 
time, such as irritable bowel syndrome (IBS). 
Pharmacological agonists of the 5-HT4R have been trialled 
for IBS; however, significant side effects can occur due to 
activation of this receptor on other cell types, such as heart 
muscle cells. Thus, specific delivery of a 5-HT4R ligand to 
the gut would be a desirable treatment option [56].
Effect of commensal metabolites on host immune 
function
Microbial diversity has been identified as an important 
factor in mediating immune development and maintenance 
of homoeostasis. Many inflammatory and autoimmune 
diseases are associated with dysbiosis, but whether dys-
biosis is the cause or consequence of these diseases is 
difficult to dissect. In any case, dysbiosis at least acts to 
amplify inflammation [9]. Sequencing of human micro-
biomes has revealed a wide variation in species composi-
tion, thus making it difficult to ascribe beneficial, or 
detrimental, effects to specific species. Instead, it is emerging 
that common functional activities and metabolites are 
conserved between individuals. Thus, it appears that func-
tional metabolic niche fulfilment is more important than 
specific individual species within the microbiota [9,57,58]. 
Numerous metabolites present in the circulation are 
dependent on the presence of gut microbiota [53]; thus, 
it is not surprising that the microbiota can exert effects 
on the host beyond the gut, including effects on host 
metabolism, the endocrine system, brain and peripheral 
immune and inflammatory responses [3,5,6,58–60]. This 
review will focus on a few examples of microbial metabo-
lites affecting host mucosal and peripheral immune 
responses.
Dysbiosis is commonly associated with a shift towards 
aerobes and facultative anaerobes and decreased levels of 
SCFAs [4,7,61,62]. SCFAs, acetate, propionate and butyrate, 
were found to bind G-protein coupled receptors GPR41 
and 43 with varying affinity [63,64]. In a landmark paper, 
we described a diet–microbiota–host immune axis where 
microbial metabolism of dietary fibre resulted in SCFA 
production, and acetate in particular activated GPR43 on 
innate immune cells, including eosinophils and neutrophils 
[65]. Acetate ligation of GPR43 on neutrophils affected 
chemotaxis, reactive oxygen species (ROS) and phagocytic 
activity. In the absence of microbiota, colitis and arthritis 
was exacerbated, and this could be rescued by addition 
of acetate in the drinking water [65]. Mice lacking Gpr43 
also exhibited exacerbated colitis, arthritis and allergic 
airway responses, which could not be rescued by addition 
of acetate to the drinking water [65]. Numerous other 
effects of SCFA, whether receptor-dependent or -inde-
pendent have now been reported [66–69].
Antibiotic treatment-induced dysbiosis can have wide-
reaching effects, for example on inflammation, infection 
and responses to vaccination [70–72]. Antibiotics have been 
shown to affect SCFA-producing bacteria causing a decrease 
in SCFA abundance [73,74]. In a recent study, macrophage 
dysfunction was noted following antibiotic-induced dys-
biosis causing aberrant activation of T helper type 1 (Th1) 
cells, leaving mice susceptible to Th17 and Th2-type infec-
tions [75]. The authors demonstrated that SCFA were 
reduced following antibiotics, and that supplementing 
butyrate could restore macrophage hyporesponsiveness to 
microbial ligands and prevent Th1 over-activation [75], 
thus showing a wider effect of antibiotics on the host 
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beyond microbial composition and effects on colonization 
resistance. This observation is likely to also be applicable 
to conditions where SCFA are known to have peripheral 
effects and also suggest that antibiotic treatment would 
affect other microbial-derived metabolites.
Acetate and butyrate have also been found to affect 
IgA responses. In two separate studies, acetate was found 
to affect CD103+  dendritic cell retinol dehydrogenase 
activity resulting in increased retinoic acid (RA) produc-
tion, which increased intestinal IgA production [66,76]. 
Tan et al. additionally showed enhanced T follicular helper 
cell function supporting mucosal germinal centre reactions 
[66]. This enhanced mucosal IgA production was important 
for controlling food allergy responses, with zero fibre 
feeding, or knock-outs of Gpr43 or Gpr109A (butyrate 
receptor), being more susceptible to food allergy [66].
Within the mucosal tissue, SCFAs, butyrate in particular, 
is important for maintaining immune homoeostasis 
through induction of regulatory T cells (Tregs) [77,78]. 
Butyrate-stimulated Treg expansion in the lamina propria 
and bone marrow has been shown to promote interaction 
between bone marrow Tregs and CD8 T cells, increasing 
production of Wnt10b by CD8 T cells, which has effects 
on stromal cells and osteoclasts promoting bone forma-
tion [79]. Supplementation of Lactobacillus rhamnosus GG 
(LGG) had previously been shown to affect bone forma-
tion, but the mechanisms had not been described. In this 
study, they confirm that LGG increases bone mass via 
increased circulation of butyrate. Interestingly, LGG itself 
is not responsible for butyrate production, but promotes 
other bacterial species that produce butyrate [79], again 
highlighting the complex interplay between different micro-
bial communities and how a particular species may not 
be the key dominant factor, but rather that fulfilment of 
a metabolic niche is important for maintaining 
homoeostasis.
The maternal gut microbial composition and products, 
particularly SCFA, have been shown to affect immune 
development in offspring [80,81]. In one study, high-fibre 
feeding or supplementation with acetate reduced suscep-
tibility to allergic airway disease (AAD) in mice, and 
furthermore could supress AAD development in the off-
spring of mice fed on a high-fibre/acetate diet during 
pregnancy [80]. This, they showed, had an effect on Treg 
expression of forkhead box protein 3 (FoxP3) and block-
ing Tregs ablated the beneficial effects of acetate on AAD 
development [80]. Nakajima et al. [82] have shown that 
microbial-derived butyrate affected thymic expression of 
Aire, which is known to be important for Treg selection 
in the thymus. In further studies, they demonstrated that 
maternal delivery of butyrate increased thymic expression 
of Gpr41 and Aire and increased thymic and peripheral 
Treg numbers [81]. This study did not determine if the 
altered Treg number had any effect on peripheral immune 
responses but, coupled with the other studies described 
above, the data would suggest that SCFA can affect Treg 
development via a multitude of mechanisms [77–81].
While many studies have found effects of SCFA, other 
microbial-derived metabolites are also being discovered 
to affect immune responses. Morita et al. [83] found that 
GPR31 expression on CX3CR1+ intestinal dendritic cells 
senses bacterial-produced lactate and pyruvate and medi-
ates dendrite extension and luminal sampling. 
Supplementation of lactate or pyruvate enhanced uptake 
and immune responses to S. typhimurium infection, which 
was not afforded in Gpr31–/– mice. Engagement of lactate 
with its other receptor, Gpr81, on intestinal dendritic cells 
and macrophages was also shown to reduce colitis by 
suppressing cytokine production and Th1/Th17 cell dif-
ferentiation [84], but whether this was due to gut microbe-
generated lactate in particular was not addressed.
Effect of the host immune system on composition of 
the gut microbiota
IgA plays a critical role in controlling the composition 
and diversity of the intestinal microbiota [85,86]. The 
importance of maintaining bacterial composition by IgA 
is highlighted by the fact that people with selective IgA 
deficiency have a higher predisposition to autoimmune 
diseases [9,87]. IgA not only limits enteric pathogens 
[88,89], but also actively promotes beneficial microbes. 
For example, IgA coating enhances Bacteroides fragilis 
habitation of the mucous and mediates intimate interac-
tions with the intestinal epithelium [90].
A recent study showed further importance of IgA coat-
ing of a strain of Bacteroidetes, which was important for 
modulating interphylum bacterial interactions and co-
operation via shared metabolism [91]. Aiming to test 
whether glycan–glycan interactions between IgA, bacteria 
and mucous are important for modulating gut microbiota, 
Nakajima et al. [91] developed a highly glycosylated anti-
ovalbumin IgA monoclonal antibody. This antibody bound 
preferentially to metabolically active members of the 
Bacteriodales via glycan-lipopolysaccharide (LPS) interac-
tions. Binding of this highly glycosylated, antigen-inde-
pendent antibody altered microbial expression of 
polysaccharide utilization loci (PUL) genes, particularly 
in mucosal-associated bacteria, and not bacteria present 
in the colonic content [91]. Highly expressed PUL genes 
included components of the starch utilization system, 
which the authors propose act as symbiotic factors ena-
bling bacterial presence in the mucous environment, and 
have provisionally named them as mucous-associated 
functional factors (MAFFs) [91]. A complex interaction 
between B. thetaiotaomicron in the mucous, expression 
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of MAFFs and presence of other symbiotic partners was 
required for the full effect of MAFFs. IgA binding-induced 
expression of MAFFs drove the expansion of butyrate-
producing Clostridiales and promoted colonic homoeostasis 
protecting in a model of colitis [91]. IgA has been known 
for some time to be important in regulating gut microbial 
composition [63], but this study is the first to describe 
such complex interplay between a host factor (IgA), micro-
bial selection in a given niche and interphylum microbial 
interaction, resulting in metabolites that benefit the host.
IgA has also been suggested to limit microbial metabolite 
penetration, thus impacting on the host response to micro-
bial metabolites [92]. Uchimura et al. [92] colonized 
germ-free mice with a replication-deficient Escherichia coli 
which had been grown in 12C-labelled medium, enabling 
them to trace metabolites that originated from the bac-
teria  within tissues and urine. Because of the transient 
colonization, they could compare between mice that had 
received no prior colonization and those that had and 
therefore had IgA induction. They found that IgA pro-
moted the clearance of metabolites from the host tissues 
by accelerating microbial clearance [92]. While this study 
was able to show that IgA affects the distribution of 
metabolites in this setting, which would be in agreement 
with other studies showing the importance of IgA in 
selecting bacterial species and affecting the time bacteria 
reside in the gut [85,86,89], whether the same kind of 
effects would be applicable in the more complex setting 
of a colonized gut is uncertain. For example, several stud-
ies show that IgA can increase the dwell time of certain 
bacteria, which can have follow-on effects on the wider 
microbial composition and metabolite availability [90,91]. 
Nevertheless, all these studies demonstrate the importance 
of IgA in the regulation of the microbiota composition, 
which thereby affects metabolic activity of the microbiome 
and metabolites released into the host system.
Metabolic interplay between host, microbiota and 
pathogens
Some of the studies discussed above describe examples 
of interphylum co-operation via metabolites. This section 
expands on that theme and will highlight some examples 
of co-infections relying on metabolic subversion, or uti-
lization of certain metabolites, to aid infection or promote 
host responses.
A type 2 innate immune circuit between the microbiota, 
intestinal tuft cells and group 2 innate lymphoid cells 
(ILC2s) has been described by several groups [93–95]. 
Intestinal tuft cells are a population of chemosensory cells 
that can be found in the airways, trachea and intestinal 
tract [96]. In the small intestine they have been described 
to produce interleukin (IL)-25 upon helminth infection. 
This initiates IL-13 production by ILC2s, which feeds back 
on epithelial progenitor cells and biases their differentia-
tion into goblet and tuft cells, thus promoting a positive 
feed-forward loop that promotes worm clearance [93–95]. 
Recent reports found that the tuft cell–ILC2 circuit could 
be induced by microbial-derived succinate binding to 
G-protein coupled receptor 91 (GPR91, also known as 
succinate receptor 1, SUCNR1) [97–100]. SUCNR1 is 
specifically expressed on small intestinal tuft cells, and 
ligation with succinate induces a downstream chemosens-
ing pathway involving α-gustducin (Gnat3) and Trpm5. 
Supplementing succinate in the drinking water was suf-
ficient to activate SUCNR1 and induce the IL-25–ILC2–
IL-13-driven expansion of goblet and tuft cells. Succinate 
produced by the protist Tritrichomonas also drove a type-2 
response through SUCNR1 signalling. In the context of 
helminth infection, however, SUCNR1 signalling appeared 
redundant or absent, although downstream activation of 
Trpm5 and IL-25 occurs [99,100], although one of these 
studies showed that activation of this type 2 circuit by 
Tritrichomonas-derived succinate protected from subse-
quent infection with helminths [97]. This would suggest 
that the expansion of goblet and tuft cells is important 
for limiting infection with helminths. Even though hel-
minths may be able to produce succinate during infection, 
helminth-derived succinate does not induce SUCNR1 
signalling. This may be due to suppression of succinate 
production, use of alternative pathways or perhaps locali-
zation of succinate production.
Several studies have shown the important effects of 
aryl hydrocarbon receptor (AHR) ligands on the gut epi-
thelium, maintaining the stem cell niche, barrier function 
and protection from tumorigenesis and infection [101], 
as well as important effects on immune cells and periph-
eral inflammatory responses [102,103]. AHR ligands also 
regulate mucosal immunity through induction of IL-22, 
a cytokine important for epithelial restitution, induction 
of anti-microbial peptides and regulation of inflammation 
[104]. Zelante et al. [105] found that tryptophan metabo-
lism by stomach-resident commensal Lactobacillus reuteri 
resulted in indole-3-aldehyde production (IAld), which 
they showed activated AHR signalling in NKp46+  cells 
(and possibly also other cell types) which increased IL-22 
production by stomach epithelia. This, they demonstrated, 
was important for resistance against Candida albicans 
infection [105]. Increasing tryptophan supply by dietary 
supplementation, or deletion of host indolamine 2,3-dioxy-
genase 1 (IDO1), increased levels of the tryptophan 
metabolite IAld specifically (due to enzymatic pathways 
present in L. reuteri), which mediated these effects [105].
Caspase recruitment domain-containing protein 9 
(CARD9) is a signalling adaptor protein involved in inte-
grating signals from a range of innate receptors, including 
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C-type lectin and nucleotide-binding oligomerization 
domain-like (NOD) receptors, and is thus involved in 
bacterial, viral and fungal immune responses [106]. CARD9 
deficiency was found to affect gut microbial composition 
and had a resultant effect on tryptophan metabolism [107]. 
Reductions in certain bacterial populations, including L. 
reuteri and Allobaculum sp., was associated with dimin-
ished indole-3-acetic acid (IAA) production in the colon 
[107]. Accordingly, faeces from CARD9–/– mice had 
reduced ability to activate an AHR reporter, indicating 
the potential of microbial-derived IAA to signal through 
AHR. CARD9–/– mice were more susceptible to colitis, 
in concordance with CARD9 being a risk allele for IBD 
in humans. Adding an AHR agonist rescued IL-22 and 
adenosine monophosphate (AMP) production and pro-
tected from colitis in CARD9–/–, again showing the impor-
tance of AHR ligands in promoting IL-22 production 
and epithelial barrier function. Furthermore, IL-22 itself 
alters microbial composition, particularly reducing 
Lactobacillus sp. [107,108], probably through the produc-
tion of AMPs, and thereby affects tryptophan metabolism, 
forming a cyclical relationship between microbial trypto-
phan metabolism, AHR agonism, IL-22 production and 
modulation of the intestinal epithelium [107].
IL-22 production is increased upon enteric infection 
and is protective against some pathogens, such as 
Citrobacter rodentium, and colitis, as discussed above and 
elsewhere [107,109–111]. However, IL-22 can promote 
colonization by other pathogens such as S. typhimurium 
by controlling growth of its niche competitor E. coli [112]. 
In a study by Grizotte-Lake et al. [113] they found that 
commensal microbes suppress small intestinal epithelial 
expression of Rdh7, an enzyme required for retinoic acid 
(RA) production, resulting in reduced RA in SPF mice 
compared to germ-free mice. This effect was due to spore-
forming Clostridia sp. The reduction in RA in SPF mice 
resulted in diminished IL-22 production by ILC3s and 
other T cell populations. To understand the effects of 
Rdh7, they used Rdh7–/– mice and could recapitulate the 
reduction in RA and IL-22. This resulted in decreased 
production of AMPs by the small intestinal epithelium 
which led to alterations in the gut microbiota, and pro-
moted host resistance to S. typhimurium infection (there 
was no effect on C. rodentium infection). Along with the 
studies described above [107,108], this suggests that a 
degree of tonic regulation of IL-22 mediated by the gut 
microbiota is important for modulating gut microbial 
composition and also susceptibility to intestinal pathogens. 
This highlights how these networks need to be finely tuned 
in order to promote homoeostatic interactions between 
host and commensals while limiting pathogens.
Pathogens can alter the gastrointestinal environment 
to enable them to thrive. Salmonella spp. virulence 
factors induce inflammation in the mucosa characterized 
by neutrophil recruitment. Neutrophils, and the inflam-
mation induced, release a large amount of electron 
acceptors, such as tetrathionate and nitrate, which fuel 
Salmonella metabolism, allowing their expansion while 
altering the gut microbial composition, including the 
depletion of Clostridia spp. [114,115]. This causes a 
reduction in butyrate which alters metabolic activity of 
enterocytes which usually rely on butyrate, as discussed 
above, and thus leads to increased oxygen availability, 
further supporting Salmonella growth [7]. Changes in 
enterocyte metabolism were found to generate lactate 
which, along with the increase in oxygen, Salmonella 
could use as an energy source with oxygen as the final 
electron acceptor [70]. Furthermore, it was recently 
reported that Salmonella can utilize microbiota-derived 
succinate and host-derived electron acceptors to enable 
a complete oxidative tricarboxylic acid (TCA) cycle [116]. 
Thus, pathogens such as Salmonella spp. can actively 
induce dysbiosis, or dysbiosis through other causes can 
support the growth of Salmonella.
More complex interactions between host and microbial 
species can occur in co-infection settings. Chronic hel-
minth infections are associated with increased occurrence 
of co-infections with a range of bacterial and viral patho-
gens [117–120]. Induction of type 2 (Th2) immune 
responses and Tregs is thought to play a major role in 
limiting protective Th1 and Th17 responses required to 
clear bacterial and viral pathogens [118–121]. Helminth 
infections can alter the microbial composition and have 
been shown to increase SCFA production, which can 
alleviate allergic airway inflammation and colitis [122,123]. 
Using a co-infection model, Reynolds et al. [124] found 
that helminth infection (Heligmosomoides polygyrus) 
altered the metabolome of small intestinal epithelial cells, 
which has a resultant effect on Salmonella expression of 
invasion genes within the Salmonella pathogenicity island-1 
(SPI-1). Metabolites extracted from naive small intestinal 
epithelial cells could supress SPI-1 expression and reduce 
invasion of Salmonella in an in-vitro invasion assay, whereas 
helminth-infected epithelial metabolites could not, and 
thus increased Salmonella invasion was observed if mice 
were already infected with helminths [124]. This study 
did not identify individual metabolites that exert this effect, 
so whether individual or multiple metabolites are respon-
sible is yet to be determined. Given that helminths, or 
helminth-derived products, are of interest as therapeutic 
interventions for allergic airway and inflammatory bowel 
disease, it is important to understand possible negative 
impacts they may have in promoting co-infections [124].
Altogether, these studies highlight the complex interac-
tions between host and microbes, as well as intermicrobial 
interactions, many of which are mediated by, or involve 
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subversion of, metabolic pathways and metabolites. 
Epithelial metabolism and physiological hypoxia are central 
to the host–microbe relationship. As colonocytes are dif-
ferentiated at the top of the crypts they express PPARγ, 
which switches on β-oxidation of butyrate and oxidative 
phosphorylation which consumes oxygen. By the induc-
tion of physiological hypoxia, HIF becomes stabilized and 
then induces transcription of essential genes required for 
epithelial barrier function, such as tight junction proteins, 
anti-microbial peptides and mucous production. The 
hypoxic environment created then favours obligate anaer-
obes which act in a mutualistic relationship, providing 
the main energy source, butyrate, for the colonocytes by 
fermentation of dietary fibre (Fig. 1). This establishes 
obligate anaerobes as the dominant bacteria within the 
colon, and further metabolites derived from the microbiota, 
such as acetate, lactate, AHR ligands, indole-derived mol-
ecules, etc. are now appreciated to exert a broad range 
of effects on immune and host function, as well as feeding 
back to select the  microbiome further via IgA or anti-
microbial peptides. These processes, from epithelial metab-
olism to maintenance of obligate anaerobes, are disrupted 
during infections, even purposefully, favouring facultative 
anaerobes or aerobes, which can have deleterious effects 
on the host.
Future considerations in this area would be to under-
stand more clearly the development of epithelial metabolic 
pathways, understand any differences between small intes-
tine and the colon and how fluctuations in oxygen could 
be affecting the microbiome and therefore host function. 
As discussed above, constant feeding leading to increased 
blood flow and oxygenation in the intestinal tract could 
be deleterious and one way by which a western lifestyle 
may be causing dysbiosis and increased susceptibility to 
inflammatory diseases. It is also of interest that chronic 
bowel inflammation, such as in Crohn’s disease or ulcera-
tive colitis, causes increased angiogenesis in the intestinal 
tract, and thus increased oxygen availability might be one 
reason for poor treatment outcomes in many patients, 
where dysbiosis and ongoing inflammation are concomitant 
factors [125]. In addition to increased angiogenesis, intes-
tinal inflammation is also associated with bleeding in to 
the gut lumen, which also delivers increased haem-bound 
oxygen. As such, targeting oxygen has been proposed as 
a treatment option for inflammatory bowel diseases [8].
Some obligate anaerobic commensals cope with oxygen 
by employing mechanisms such as extracellular electron 
shuttles, which add electrons to oxygen. This relies upon 
flavins and thiols being present in the gut; however, dur-
ing inflammation thiols become depleted [8,126]. Faecal 
microbiota transplant has been employed successfully for 
C. difficile-infected patients, and is entering use for further 
conditions from inflammatory bowel disease to asthma 
and cancer treatment. However, defining ‘good’ faecal 
donors is a challenge, and presence of microbial species 
that are good colonizers and have traits such as being 
able to utilize and deplete oxygen may be an important 
consideration.
In summary, metabolism and metabolites are the basis 
of host–microbe interactions. Further understanding of 
these metabolic interactions will be important for devel-
oping treatment strategies for inflammatory bowel diseases 
as well as the wide range of other diseases associated 
with dysbiosis.
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